Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical valproate has minimal potential to cause skin irritation, suggesting it can be applied safely to human skin.

In this study, Biosea® Revive serum, containing biotinoyl tripeptide-1 and Phyllanthus emblica extract, was found to improve hair density and quality in a 90-day clinical trial without adverse effects, offering a potential natural solution for hair growth.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

Dermatologist visits offer safer and more ethical treatment for hair loss than direct-to-consumer platforms.

Intense pulsed light with radiofrequency showed mixed results in improving quality of life for hidradenitis suppurativa patients, with no clinical improvements.

This study observed that long-term use of finasteride in Japanese men with androgenetic alopecia was associated with progressive hair regrowth in 87.1% of participants without significant safety concerns.

This study found that combining celecoxib with chemotherapy improved overall survival, disease-free survival, and quality of life in gastric cancer patients with positive COX-2 expression without increasing adverse events.

In this study, Saudi Arabian women showed moderate awareness of eyebrow microblading, yet many lacked knowledge of hygiene practices, indicating a need for more public education on the procedure's risks and standards.

This study found that the Ayurvedic formulation Trichup Capsule significantly increased hair length and diameter in treated animals without signs of toxicity or mortality.

This review suggests that certain nutritional supplements may have a potential role in improving hair loss, though evidence quality varies, and such treatments should be discussed collaboratively between physicians and patients.

This study found that treatment with fractional 1064 nm picosecond Nd:YAG laser effectively reduced post-acne erythema in adult Chinese patients without causing scarring or pigmentation issues, though some experienced temporary erythema, oedema, pruritus, and acne eruptions.

This pilot study suggests that platelet-rich plasma may be a promising treatment for chronic telogen effluvium with good safety, and cost-effective preparation methods may be reliable alternatives to more expensive ones.

This study found that intradermal administration of QR678 Neo® significantly reduced hair fall and improved hair growth in patients with androgenetic alopecia and female pattern hair loss, with no side effects reported during long-term follow-up.

This study found that PRP therapy was effective and safe for treating androgenic alopecia, promoting 30% hair growth and showing antimicrobial activity against certain bacteria in affected patients.

In this study, Xtressé™ gummies were found to be safe and well tolerated, showing potential improvement in hair density among women with non-scarring alopecia over four months, while partially benefiting those with scarring alopecia; larger trials are encouraged.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

In this study, both finasteride and dutasteride were effective for androgenetic alopecia, but dutasteride significantly improved hair density more than finasteride and had a comparable safety profile among men treated at an Indian center.

This study at Gajra Raja Medical College found that topical methotrexate with tretinoin was more effective but not significantly better than betamethasone with tretinoin for treating alopecia areata over six months, with similar safety profiles between the treatments.

This study reported significant improvements in hair density and growth ratio in androgenetic alopecia patients receiving concentrated growth factor injections, with benefits sustained for 6 months.

This review suggests that low-dose oral minoxidil may be a safe option for treating hair disorders in children, while moderate and high doses may not be safe.

This study found that the ThriveCo Anti-Dandruff Pre-Shampoo Treatment, containing ZenscalpinTM, significantly reduced dandruff by 54.79% after 8 days and improved scalp health, with most participants reporting reduced flaking, dryness, and itchiness, and no noted adverse events.

This pilot study found that using polydioxanone monofilament threads for scalp stringing resulted in significant hair regrowth and increased hair density in male patients with vertex androgenetic alopecia (crown baldness) over six months, showing favorable and promising outcomes.

In this study at Al-Diwaniyah Teaching Hospital, oral cyclosporine effectively treated 80% of patients with alopecia areata without significant adverse effects, showing promise as a safe treatment option.

This study found that a hair lotion containing saw palmetto and 10% trichogen veg complex increased total hair count in male patients with androgenetic alopecia over four months, though observer assessments varied.

In this study, researchers administered intravenous autologous activated platelet-rich plasma (aaPRP) to 611 patients and reported no adverse events, suggesting that this treatment is safe even for patients with various pathological conditions.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.